Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NT-112: Autologous, engineered T Cells targeting KRAS G12D
NT-112 · 1 trial · 6 indications
Incidence of DLTs, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence of DLTs, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Incidence of DLTs, treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| NT-112 | EXPERIMENTAL | Part A Dose Escalation and Part B Dose Expansion of NT-112 |
| AZD0240 | EXPERIMENTAL | Part A Dose Escalation and Part B Dose Expansion of AZD0240 |
| Name | Type | Description |
|---|---|---|
| NT-112: Autologous, engineered T Cells targeting KRAS G12D | BIOLOGICAL | NT-112 targets KRAS G12D in the context of HLA-C\*08:02 |
| AZD0240: Autologous, engineered T Cells targeting KRAS G12D | BIOLOGICAL | AZD0240 targets KRAS G12D in the context of HLA-A\*11:01 or HLA-A\*11:02 |
Key Inclusion Criteria: * Age ≥18 years * Diagnosed with NSCLC, Colorectal adenocarcinoma, Pancreatic adenocarcinoma, Endometrial Cancer or any other solid tumor * Tumors must harbor a KRAS G12D variant mutation and subject must be HLA-C\*08:02 positive, HLA-A\*11:01 or HLA-A\*11:02 positive in at ...
Top 20 of 83 competitors